Stealth BioTherapeutics (MITO) Tops Q1 EPS by 5c

Stealth BioTherapeutics (NASDAQ: MITO) reported Q1 EPS of ($0.04), $0.05 better than the analyst estimate of ($0.09).

"Our industry – and our global community – is facing unprecedented challenges due to the COVID-19 pandemic. In these trying times, Stealth is fortunate to have strong shareholder support, leaving us well-capitalized into 2021, with enthusiastic and focused employees, who have shown tremendous dedication to developing mitochondrial medicines for patients suffering from cardiomyopathic, ophthalmic, neurological and neuropathic disorders," said Reenie McCarthy, chief executive officer of Stealth. "Our team has rallied remarkably to work to ensure the continued progress of our ongoing clinical and regulatory efforts and the safety of our patients. We look forward to additional regulatory interactions regarding our Barth program, hopefully, over the summer and hope to see an uptick in enrollment in our Phase 2b study in dry AMD as various regions of the country reopen in the coming weeks. We are also continuing our efforts to expand our rare metabolic cardiomyopathy franchise and advance our pipeline of novel mitochondrial medicines."

For earnings history and earnings-related data on Stealth BioTherapeutics (MITO) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c